Literature DB >> 19224409

Misdiagnosis of bipolar disorder as borderline personality disorder: clinical and economic consequences.

Hyacinth John1, Verinder Sharma.   

Abstract

We report the case of a 26-year-old patient with bipolar spectrum disorder who was misdiagnosed with borderline personality disorder. In spite of trials of various psychotropic drugs and frequent, prolonged hospitalizations, the patient had remained chronically symptomatic. Following a detailed examination of the longitudinal illness course and confirmation of the diagnosis of bipolar spectrum disorder, antidepressants were discontinued and the patient was treated with lamotrigine and quetiapine. This treatment resulted in sustained euthymia and cessation of deliberate self-harm in addition to a significant reduction in utilization of health resources.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224409     DOI: 10.1080/15622970701816522

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  2 in total

1.  Regulation of gene transcription in bipolar disorders: Role of DNA methylation in the relationship between prodynorphin and brain derived neurotrophic factor.

Authors:  Claudio D'Addario; Maria Carlotta Palazzo; Beatrice Benatti; Benedetta Grancini; Mariangela Pucci; Andrea Di Francesco; Giulia Camuri; Daniela Galimberti; Chiara Fenoglio; Elio Scarpini; A Carlo Altamura; Mauro Maccarrone; Bernardo Dell'Osso
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-08-19       Impact factor: 5.067

2.  Diagnose, indicate, and treat severe mental illness (DITSMI) as appropriate care: A three-year follow-up study in long-term residential psychiatric patients on the effects of re-diagnosis on medication prescription, patient functioning, and hospital bed utilization.

Authors:  H M Veereschild; E O Noorthoorn; H L I Nijman; C L Mulder; M Dankers; J A Van der Veen; A J M Loonen; G J M Hutschemaekers
Journal:  Eur Psychiatry       Date:  2020-05-08       Impact factor: 5.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.